Will Aldeyra Hit the Bull’s Eye in Dry Eye?
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) announced positive results from the Phase 3 tranquility trial, which achieved its primary endpoint of being statistically superior to the vehicle for each of the two prespecified primary endpoints, Schirmer test (p=0.0001) and ≥10 mm Schirmer test responder proportions (p<0.0001)...
